Genmab Stock - analyst consensus and long-term outlook

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 14:05 CET. Details in the imprint.

Genmab (DK0010272202) remains a widely followed European biotech name on Nasdaq and in Copenhagen. With no new investor-relations releases or major news from Reuters or Bloomberg in the past day, the stock narrative is currently shaped mainly by analyst consensus and its established antibody platform.

What analysts currently expect

Consensus data compiled by several financial portals show that most covering banks remain constructive on Genmab, with an average rating in the Buy to Hold range and a wide spread of price targets around the current market price.

Analysts typically highlight the company’s royalty streams from partnered drugs such as Darzalex and Tepezza, alongside its own pipeline, as key value drivers; they also flag patent cliffs and competitive antibody platforms as the main medium-term risks.

Long-term drivers and business model

Genmab has built its strategy around antibody discovery platforms and a partnership-heavy model, which limits manufacturing risk but caps upside on some assets through revenue-sharing and milestone structures with larger pharma partners.

The company reports solid liquidity and no excessive leverage, which allows management to keep investing in R&D through clinical cycles that can run for many years before commercial traction becomes visible on the income statement.

The product behind the stock

At the core of Genmab’s business is its portfolio of antibody-based therapies, most prominently cancer drug Darzalex, developed with Johnson & Johnson, which generates recurring royalties and helps fund the company’s broader oncology-focused research pipeline.

Where the stock trades today

Genmab shares trade on the Nasdaq under the ticker GMAB and on Nasdaq Copenhagen under GMAB, with the latest available closing price on Nasdaq at approximately $25.27 on 06/18/2026, according to recent market data.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.